MerTK blocking with a specific antibody leads to inhibition of TAM-mediated efferocytosis of apoptotic tumor cells that activate an inflammatory type I IFN response through the induction of the stimulator of interferon genes (STING)-controlled innate immune pathway, with subsequent CD8+ activation and a synergistic effect with anti-PD1/PDL1 checkpoint inhibitors [64]. This evidence concerns the gene MERTK and neoplasm.